TP53 and mesenchymal cell neoplasm: Site-specific expression of Cre recombinase in the Oncopig resulted in localized p53 inhibition and KRAS activation; subcutaneous injection of AdCre produced mesenchymal tumors at the injection sites31 in non-immunosuppressed Oncopigs.